Tiziana Life Sciences Ltd. (TLSA), a biotech firm focused on immunomodulation therapies, announced that its Executive Chairman and Founder, Gabriele Cerrone, has acquired 15,000 additional common shares at $1.55 each.
This purchase increases his total holdings to 43,252,143 shares, representing 37.02% of the company's issued share capital.
TLSA is currently trading at $1.5099 or 3.8280% lower on the Nasdaq Capital Market.
For comments and feedback: editorial@rttnews.com